BankPlus Trust Department’s CRISPR Therapeutics CRSP Stock Holding History

BankPlus Trust Department’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-100	Closed	-$4.76K	–	477
2026 Q1	$4.76K	Hold	100	–	–	﹤0.01%	409
2025 Q4	$5.24K	Hold	100	–	–	﹤0.01%	402
2025 Q3	$6.48K	Hold	100	–	–	﹤0.01%	382
2025 Q2	$4.86K	Hold	100	–	–	﹤0.01%	386
2025 Q1	$3.4K	Buy	+100	New	+$4.24K	﹤0.01%	420

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

GSK plc London $602M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

BankPlus Trust Department's CRSP Position: Q2 2026 in Review

BankPlus Trust Department sold out of CRISPR Therapeutics (CRSP) in Q2 2026, closing a stake of 100 shares — an estimated $4.76K sold.

BankPlus Trust Department first reported a position in CRSP in Q1 2025 and held it in 5 quarters. The position peaked at $6.48K in Q3 2025. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

BankPlus Trust Department reported no remaining CRISPR Therapeutics position as of Q2 2026 after selling out during the quarter.
BankPlus Trust Department sold 100 CRISPR Therapeutics shares in Q2 2026, an estimated $4.76K.
BankPlus Trust Department first reported a position in CRISPR Therapeutics in Q1 2025 and held it in 5 quarters.
BankPlus Trust Department's CRISPR Therapeutics position peaked at $6.48K in Q3 2025.
524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on BankPlus Trust Department's 13F filing for Q2 2026, filed 28 Jul 2026.